Boston, Massachusetts–(Newsfile Corp. – November 29, 2023) – Block & Leviton is investigating BioVie, Inc. (NASDAQ: BIVI) for potential securities law violations. Investors who have lost money in their BioVie, Inc. investment should contact the firmÂ to learn more about how they might recover those losses. For more details, visit https://www.blockleviton.com/cases/bivi.
What is this all about?
Before the market opened on November 29, 2023, BioVie, Inc. announced that its Phase 3 trial of NE3107 for treatment of mild to moderate Alzheimer’s Disease missed statistical significance due to exclusions. BioVie found significant deviation from protocol and Good Clinical Practice violations at 15 sites, that resulted in all patients from those sites being excluded and referred to the FDA Office of Scientific Investigations.
Shares of BioVie, Inc. stock dropped more than 60% in both premarket and intraday trading on November 29, 2023.
Who is eligible?
Anyone who purchased BioVie, Inc. stock and has lost money may be eligible, whether or not they have sold their investment. Investors should contact Block & Leviton to learn more.
What is Block & Leviton doing?
Block & Leviton is investigating whether the Company committed securities law violations and may file an action to attempt to recover losses on behalf of investors who have lost money.
What should you do next?
Why should you contact Block & Leviton?
Block & Leviton is widely regarded as one of the leading securities class action firms in the country. We have obtained, and are dedicated to obtaining significant recoveries on behalf of defrauded investors through active litigation in the federal courts across the country. Many of the nation’s top institutional investors hire us to represent their interests. You can learn more about us at our website, www.blockleviton.com, or call (617) 398-5600 or email firstname.lastname@example.org with any questions.
This notice may constitute attorney advertising.
BLOCK & LEVITON LLP
260 Franklin St., Suite 1860
Boston, MA 02110
Phone: (617) 398-5600
SOURCE: Block & Leviton LLP
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/189110
This article is for the purposes of solicitation subscriptions for this website. This website expects to generate new advertisement revenue resulting from the distribution of this article. The amount of which is unknown at this time. This website or it’s authors do not own any shares of BioVie Inc. (BIVI) and does not buy, sell, or trade any shares of (BIVI). This article does not provide a professional analysis of a (BIVI) financial position. (BIVI) financial position and all other information regarding the featured Company should be verified directly with (BIVI). Please read our full disclaimer for more detailed information.